Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 13Recruiting 5Active not recruiting 3Unknown 1Terminated 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Lymphoid 1

Conditions

Prostatic Neoplasms 2Waldenstrom Macroglobulinemia 1

Interventions

pembrolizumab 438Carboplatin 321Nivolumab 293Cyclophosphamide 285Specimen Handling 257Paclitaxel 249Magnetic Resonance Spectroscopy 249Cisplatin 248Radiotherapy 218Dexamethasone 183Gemcitabine 177Biopsy 177durvalumab 169atezolizumab 149Doxorubicin 140Rituximab 138Lenalidomide 135Docetaxel 131Ipilimumab 130Bevacizumab 128Radiation 121Capecitabine 117Etoposide 116Oxaliplatin 114Fluorouracil 110Pemetrexed 109Radiosurgery 108fludarabine 106venetoclax 102Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × Valacyclovir × Clear all
NCT00492050 2026-03-11

Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
46 enrolled 10 charts
Lymphoid

Waldenstrom Macroglobulinemia

NCT01436968 2025-07-30

PrTK03

Candel Therapeutics, Inc.

Phase 3 Active not recruiting
711 enrolled
Genitourinary

Prostatic Neoplasms

NCT02768363 2025-07-30

Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)

Candel Therapeutics, Inc.

Phase 2 Active not recruiting
187 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡